SCHEMBL496361

SCHEMBL496361

CN1C(=O)CCc2ccc(NC(=O)c3ccc(C(F)(F)F)cc3N[C@H]3CCCC[C@@H]3OCc3ccccc3)cc21

nearest known ligand 0.48

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 17/20 0.48
TACR1 P25103 2/20 0.41
RXFP1 Q9HBX9 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL496257 0.85 TRPV1 (0.53) TRPV1RXFP1
SCHEMBL496552 0.82 TRPV1 (0.49) TRPV1
SCHEMBL495908 0.80 TRPV1 (0.47) TRPV1
SCHEMBL495678 0.79 TACR1 (0.46) TACR1
SCHEMBL496279 0.79 TRPV1 (0.55) TRPV1
SCHEMBL10129633 0.77 TRPV1 (0.53) TRPV1
SCHEMBL10129648 0.77 TRPV1 (0.53) TRPV1
Hydrochloric Acid SCHEMBL496323 0.77 TRPV1 (0.51) TRPV1
Hydrochloric Acid SCHEMBL496044 0.76 TRPV1 (0.50) TRPV1
SCHEMBL495648 0.75 TRPV1 (0.52) TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1955697-B1 2-AMINOBENZAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) INHIBITORS USEFUL FOR THE TREATMENT OF PAIN OR BLADDER FUNCTION DISORDER ASTELLAS PHARMA INC (JP) 2012-05-02 EP disclosed
US-8106190-B2 2-aminobenzamide derivatives ASTELLAS PHARMA INC. (JP) 2012-01-31 US disclosed
US-20090233900-A1 2-AMINOBENZAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-09-17 US disclosed
EP-1955697-A1 2-AMINOBENZAMIDE DERIVATIVE Astellas Pharma Inc. (JP) 2008-08-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233900-A1 2-AMINOBENZAMIDE DERIVATIVE TRPV1, TRPV2, TRPV5 TRPV1 1/4885TACR1 325/4885RXFP1 577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.